Eva Holzhäuser1, Maximilian Berlin2, Daniel Wollschläger3, Thomas Bezold2, Arnulf Mayer2, Georg Heß4, Heinz Schmidberger2. 1. Department of Radiation Oncology and Radiotherapy, University Medical Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany. eva.holzhaeuser@unimedizin-mainz.de. 2. Department of Radiation Oncology and Radiotherapy, University Medical Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany. 3. Institute for Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Obere Zahlbacher Str. 69, 55131, Mainz, Germany. 4. Department of Internal Medicine, University Medical Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.
Abstract
PURPOSE: Radiotherapy (RT) in combination with chemoimmunotherapy is highly efficient in the treatment of diffuse large B‑cell lymphoma (DLBCL). This retrospective analysis evaluated the efficacy of the treatment volume and the dose concept of involved-site RT (ISRT). PATIENTS AND METHODS: We identified 60 histologically confirmed stage I-IV DLBCL patients treated with multimodal cytotoxic chemoimmunotherapy and followed by consolidative ISRT from 2005-2015. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier method. Univariate analyses were performed by log-rank test and Mann-Whitney U‑test. RESULTS: After initial chemoimmunotherapy (mostly R‑CHOP; rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone), 19 (36%) patients achieved complete response (CR), 34 (64%) partial response (PR) or less. Excluded were 7 (12%) patients with progressive disease after chemoimmunotherapy. All patients underwent ISRT with a dose of 40 Gy. After a median follow-up of 44 months, 79% of the patients remained disease free, while 21% presented with failure, progressive systemic disease, or death. All patients who achieved CR after chemoimmunotherapy remained in CR. Of the patients achieving PR after chemotherapy only 2 failed at the initial site within the ISRT volume. No marginal relapse was observed. Ann Arbor clinical stage I/II showed significantly improved PFS compared to stage III/IV (93% vs 65%; p ≤ 0.021). International Prognostic Index (IPI) score of 0 or 1 compared to 2-5 has been associated with significantly increased PFS (100% vs 70%; p ≤ 0.031). Postchemoimmunotherapy status of CR compared to PR was associated with significantly increased PFS (100% vs 68%; p ≤ 0.004) and OS (100% vs 82%; p ≤ 0.026). Only 3 of 53 patients developed grade II late side effects, whereas grade III or IV side effects have not been observed. CONCLUSION: These data suggest that a reduction of the RT treatment volume from involved-field (IF) to involved-site (IS) is sufficient because no marginal failures occurred. The concept of IS will likely reduce the risk for late sequelae of RT.
PURPOSE: Radiotherapy (RT) in combination with chemoimmunotherapy is highly efficient in the treatment of diffuse large B‑cell lymphoma (DLBCL). This retrospective analysis evaluated the efficacy of the treatment volume and the dose concept of involved-site RT (ISRT). PATIENTS AND METHODS: We identified 60 histologically confirmed stage I-IV DLBCL patients treated with multimodal cytotoxic chemoimmunotherapy and followed by consolidative ISRT from 2005-2015. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier method. Univariate analyses were performed by log-rank test and Mann-Whitney U‑test. RESULTS: After initial chemoimmunotherapy (mostly R‑CHOP; rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone), 19 (36%) patients achieved complete response (CR), 34 (64%) partial response (PR) or less. Excluded were 7 (12%) patients with progressive disease after chemoimmunotherapy. All patients underwent ISRT with a dose of 40 Gy. After a median follow-up of 44 months, 79% of the patients remained disease free, while 21% presented with failure, progressive systemic disease, or death. All patients who achieved CR after chemoimmunotherapy remained in CR. Of the patients achieving PR after chemotherapy only 2 failed at the initial site within the ISRT volume. No marginal relapse was observed. Ann Arbor clinical stage I/II showed significantly improved PFS compared to stage III/IV (93% vs 65%; p ≤ 0.021). International Prognostic Index (IPI) score of 0 or 1 compared to 2-5 has been associated with significantly increased PFS (100% vs 70%; p ≤ 0.031). Postchemoimmunotherapy status of CR compared to PR was associated with significantly increased PFS (100% vs 68%; p ≤ 0.004) and OS (100% vs 82%; p ≤ 0.026). Only 3 of 53 patients developed grade II late side effects, whereas grade III or IV side effects have not been observed. CONCLUSION: These data suggest that a reduction of the RT treatment volume from involved-field (IF) to involved-site (IS) is sufficient because no marginal failures occurred. The concept of IS will likely reduce the risk for late sequelae of RT.
Entities:
Keywords:
Diffuse large B‑cell lymphoma; Involved-node; Involved-site; Lymphoma, non-Hodgkin; Radiotherapy
Authors: Tim Illidge; Lena Specht; Joachim Yahalom; Berthe Aleman; Anne Kiil Berthelsen; Louis Constine; Bouthaina Dabaja; Kavita Dharmarajan; Andrea Ng; Umberto Ricardi; Andrew Wirth Journal: Int J Radiat Oncol Biol Phys Date: 2014-05-01 Impact factor: 7.038
Authors: Andrea K Ng; Bouthaina Shbib Dabaja; Richard T Hoppe; Timothy Illidge; Joachim Yahalom Journal: J Clin Oncol Date: 2016-02-22 Impact factor: 44.544
Authors: J Kriz; C Baues; R Engenhart-Cabillic; U Haverkamp; K Herfarth; P Lukas; H Schmidberger; S Marnitz-Schulze; M Fuchs; A Engert; H T Eich Journal: Strahlenther Onkol Date: 2016-09-27 Impact factor: 3.621
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Lisa Lowry; Paul Smith; Wendi Qian; Stephen Falk; Kim Benstead; Tim Illidge; David Linch; Martin Robinson; Andrew Jack; Peter Hoskin Journal: Radiother Oncol Date: 2011-06-12 Impact factor: 6.280
Authors: Belinda A Campbell; Joseph M Connors; Randy D Gascoyne; W James Morris; Tom Pickles; Laurie H Sehn Journal: Cancer Date: 2012-01-17 Impact factor: 6.860
Authors: Sandra J Horning; Edie Weller; KyungMann Kim; John D Earle; Michael J O'Connell; Thomas M Habermann; John H Glick Journal: J Clin Oncol Date: 2004-06-21 Impact factor: 44.544